Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 USD | -0.33% | -1.29% | -4.97% |
Apr. 30 | B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target | MT |
Apr. 29 | HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target | MT |
Business Summary
Number of employees: 40
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 2 | 100.0 % | 0 | 100.0 % | -73.93% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 0 | 100.0 % | -73.93% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jeremy Levin
CEO | Chief Executive Officer | 70 | 14-03-31 |
Jeffrey Rona
DFI | Director of Finance/CFO | 55 | 18-12-31 |
Zhong Zhong
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-27 |
Manoj Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-07 |
Jason Tardio
COO | Chief Operating Officer | 47 | 19-11-17 |
Julia Tsai
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-07 |
Thomas Perone
CMP | Compliance Officer | 59 | 19-03-20 |
Toshiya Nishi
PRN | Corporate Officer/Principal | - | 23-02-07 |
Megan Alexander
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 15-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Barbara Duncan
BRD | Director/Board Member | 59 | 17-06-13 |
Bart Friedman
BRD | Director/Board Member | 79 | 15-11-22 |
Jeremy Levin
CEO | Chief Executive Officer | 70 | 14-03-31 |
Karen Bernstein
BRD | Director/Board Member | 71 | 15-09-29 |
Robert Poole
BRD | Director/Board Member | 67 | 21-07-08 |
Kevin Fitzgerald
BRD | Director/Board Member | 56 | 21-10-05 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 70,810,661 | 59,503,870 ( 84.03 %) | 0 | 84.03 % |
Stock B | 0 | 1,250 | 0 | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.97% | 217M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- OVID Stock
- Company Ovid Therapeutics Inc.